DaVita price target raised to $140 from $128 at Truist

Truist analyst David MacDonald raised the firm’s price target on DaVita (DVA) to $140 from $128 and keeps a Hold rating on the shares. Despite the non-discretionary nature of the service and solid cash flow, improving volume trends remain critical amid a mixed environment marked by sluggish admissions, mortality, and missed treatments, the analyst tells investors in a research note.